| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA1080461
Max Phase: Preclinical
Molecular Formula: C35H38N2O
Molecular Weight: 502.70
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C(CCCCC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1
Standard InChI: InChI=1S/C35H38N2O/c38-34(24-14-13-23-33(29-15-5-1-6-16-29)30-17-7-2-8-18-30)36-25-27-37(28-26-36)35(31-19-9-3-10-20-31)32-21-11-4-12-22-32/h1-12,15-22,33,35H,13-14,23-28H2
Standard InChI Key: DNMNLRHDLUAUHW-UHFFFAOYSA-N
Associated Targets(non-human)
Cacna2d1 Voltage-dependent L-type calcium channel subunit beta-1/alpha-1B/alpha-2/delta-1 (26 Activities)
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 502.70 | Molecular Weight (Monoisotopic): 502.2984 | AlogP: 7.31 | #Rotatable Bonds: 10 |
| Polar Surface Area: 23.55 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 0 |
| #RO5 Violations: 2 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: | CX Basic pKa: 7.30 | CX LogP: 7.81 | CX LogD: 7.55 |
| Aromatic Rings: 4 | Heavy Atoms: 38 | QED Weighted: 0.21 | Np Likeness Score: -0.56 |
References
| 1. Zamponi GW, Feng ZP, Zhang L, Pajouhesh H, Ding Y, Belardetti F, Pajouhesh H, Dolphin D, Mitscher LA, Snutch TP.. (2009) Scaffold-based design and synthesis of potent N-type calcium channel blockers., 19 (22): [PMID:19815411] [10.1016/j.bmcl.2009.09.008] |
Source
Source(1):